NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT01531361 2021-01-22Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsM.D. Anderson Cancer CenterPhase 1 Completed46 enrolled